Kardigan, Inc.

KARD

NASDAQHealthcareBiotechnology

Open in GoAI

Latest quote

$21.01

+$0.76 · +3.75%

Aug 21, 3:55 PM ET

Regular session · ET · Market data may be delayed.

Company profile

Company website

Kardigan, Inc. is a clinical-stage precision therapeutics company, which engages in developing medicines that target the root cause of specific cardiovascular diseases where no approved treatments exist. It combines clinical-stage drug programs with artificial intelligence, real-world patient data, and analytics through its “Cardiac Intelligence” platform to accelerate research and improve treatment outcomes. The company was founded by Tassos E. Gianakakos, Jay Edelberg, Bob McDowell, Leslie Leinwand, and Elizabeth McNally in August 2023 and is headquartered in Princeton, NJ.

Industry: Biotechnology
Sector: Healthcare
Headquarters: US
CEO: Tassos Gianakakos
Listed since: Jun 18, 2026
Employees: 241

Market position

Volume: 159.58K; 0.33× average
Average volume: 479.88K; Average daily volume
Market cap: 1.88B USD
Beta: 0; Market reference 1

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value: 1.22B USD
P/E (TTM): -9.82×
P/B (TTM): 3.19×
P/S (TTM): 0×
EV / EBITDA: -6.24×
Earnings yield: -14.55%
Free cash flow yield: -11.96%
Dividend yield: 0.00%

Profitability & efficiency

Gross margin: 0.00%
Operating margin: 0.00%
Net margin: 0.00%
Return on equity: 76.67%
Return on assets: -49.10%
Return on invested capital: -55.31%

Financial health

Debt / equity: 0.02×
Current ratio: 9.2×

Earnings

EPS beat rate: 0%; 0 beats, 1 miss, 0 met estimates
Average EPS surprise: -326.45%; 1 comparable report
Latest EPS result: -2.88; Estimate -0.68 · Miss by 326.45%

EPS: actual versus estimate

Recent quarterly results

ActualEstimate

Analyst ratings

Third-party consensus; not a GoAI recommendation.

Analyst price target

Average target

$38.50

83.16% upside

Past 12 months12-month forecast

Price history unavailable

High $40.00Average $38.50Low $37.00

KARD news

gurufocus.comAug 11, 2026

Kardigan Reports Second Quarter 2026 Financial Results and Recent Business Updates

Kardiganâ¢, Inc. (Nasdaq: KARD) (âKardiganâ or âthe Companyâ), a clinical-stage precision therapeutics company developing medicines that target the roo

Read source

businesswire.comAug 11, 2026

Kardigan Reports Second Quarter 2026 Financial Results and Recent Business Updates

SOUTH SAN FRANCISCO, Calif. & PRINCETON, N.J.--(BUSINESS WIRE)---- $KARD #CVD--Kardigan™, Inc. (Nasdaq: KARD) today reported financial results from the second quarter ended June 30, 2026, and provided recent business…

Read source

businesswire.comJun 22, 2026

Kardigan Announces Closing of Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares

SOUTH SAN FRANCISCO, Calif. & PRINCETON, N.J.--(BUSINESS WIRE)---- $KARD #Kardigan--Kardigan announced the closing of its initial public offering.

Read source

reuters.comJun 18, 2026

Kardigan rises in Nasdaq debut after upsized $400 million IPO

Kardigan's shares rose ‌1.6% in their Nasdaq debut on ⁠Thursday, after the heart drug developer raised $400 million in ‌an ⁠upsized U.S. initial public offering.

Read source

businesswire.comJun 17, 2026

Kardigan Announces Pricing of Upsized Initial Public Offering

SOUTH SAN FRANCISCO, Calif. & PRINCETON, N.J.--(BUSINESS WIRE)---- $KARD #Kardigan--Kardigan™, Inc. (Nasdaq: KARD) (“Kardigan”), a clinical-stage precision therapeutics company developing medicines that target the root…

Read source